Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Identifieur interne : 001137 ( PubMed/Corpus ); précédent : 001136; suivant : 001138Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Auteurs : Hisham Momattin ; Khurram Mohammed ; Alimuddin Zumla ; Ziad A. Memish ; Jaffar A. Al-TawfiqSource :
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [ 1878-3511 ] ; 2013.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Humans, Interferon-alpha (therapeutic use), Lopinavir (therapeutic use), Randomized Controlled Trials as Topic, Ritonavir (therapeutic use), SARS Virus, Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Treatment Outcome.
- MESH :
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Lopinavir, Ritonavir.
- drug therapy : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Humans, Randomized Controlled Trials as Topic, SARS Virus, Treatment Outcome.
Abstract
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.
DOI: 10.1016/j.ijid.2013.07.002
PubMed: 23993766
Links to Exploration step
pubmed:23993766Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.</title><author><name sortKey="Momattin, Hisham" sort="Momattin, Hisham" uniqKey="Momattin H" first="Hisham" last="Momattin">Hisham Momattin</name><affiliation><nlm:affiliation>Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Mohammed, Khurram" sort="Mohammed, Khurram" uniqKey="Mohammed K" first="Khurram" last="Mohammed">Khurram Mohammed</name></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A" last="Memish">Ziad A. Memish</name></author><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A" last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23993766</idno><idno type="pmid">23993766</idno><idno type="doi">10.1016/j.ijid.2013.07.002</idno><idno type="wicri:Area/PubMed/Corpus">001137</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001137</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.</title><author><name sortKey="Momattin, Hisham" sort="Momattin, Hisham" uniqKey="Momattin H" first="Hisham" last="Momattin">Hisham Momattin</name><affiliation><nlm:affiliation>Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia.</nlm:affiliation></affiliation></author><author><name sortKey="Mohammed, Khurram" sort="Mohammed, Khurram" uniqKey="Mohammed K" first="Khurram" last="Mohammed">Khurram Mohammed</name></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A" last="Memish">Ziad A. Memish</name></author><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A" last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name></author></analytic><series><title level="j">International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</title><idno type="eISSN">1878-3511</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans</term><term>Interferon-alpha (therapeutic use)</term><term>Lopinavir (therapeutic use)</term><term>Randomized Controlled Trials as Topic</term><term>Ritonavir (therapeutic use)</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Randomized Controlled Trials as Topic</term><term>SARS Virus</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23993766</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int. J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.</ArticleTitle><Pagination><MedlinePgn>e792-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2013.07.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(13)00229-4</ELocationID><Abstract><AbstractText>The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections. </AbstractText><CopyrightInformation>Copyright © 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Momattin</LastName><ForeName>Hisham</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammed</LastName><ForeName>Khurram</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zumla</LastName><ForeName>Alimuddin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Memish</LastName><ForeName>Ziad A</ForeName><Initials>ZA</Initials></Author><Author ValidYN="Y"><LastName>Al-Tawfiq</LastName><ForeName>Jaffar A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="Y">SARS Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Interferon</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">Ribavarin</Keyword><Keyword MajorTopicYN="N">SARS</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId><ArticleId IdType="pii">S1201-9712(13)00229-4</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2013.07.002</ArticleId><ArticleId IdType="pmc">PMC7110699</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Saudi Med J. 2012 Dec;33(12):1265-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23232672</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trop Med Int Health. 2004 Aug;9(8):923-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15303999</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2005 Nov;56(5):919-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16183666</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Radiology. 2003 Nov;229(2):500-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14595150</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hong Kong Med J. 2003 Aug;9(4):309; author reply 310</Citation><ArticleIdList><ArticleId IdType="pubmed">12904626</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Jun;9(6):713-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12781012</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 May;59(5):414-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15115870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect. 2013 Aug;67(2):130-40</Citation><ArticleIdList><ArticleId IdType="pubmed">23583636</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Infect. 2004 Jul;10(7):676-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15214887</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Microbiol. 2003 Aug;52(Pt 8):715-720</Citation><ArticleIdList><ArticleId IdType="pubmed">12867568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001137 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001137 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23993766
|texte= Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23993766" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |